Dendritic cells in atherosclerosis: Functions in immune regulation and beyond

Thrombosis and Haemostasis

Volumn 106, Issue 5, 2011, Pages 772-778

  Manthey, Helga D ^a   Zernecke, Alma ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Atherosclerosis; Dendritic cells; Inflammation

Indexed keywords

ALPHA INTERFERON; APOLIPOPROTEIN B100; APOLIPOPROTEIN E; CD8ALPHA ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CX3CR1; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B ANTIBODY; INTERLEUKIN 10; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADVENTITIA; ANTIGEN PRESENTATION; ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL MIGRATION; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; DENDRITIC CELL; DISEASE PREDISPOSITION; ENDOTHELIUM CELL; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOREGULATION; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MONOCYTE; NONHUMAN; PINOCYTOSIS; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

ANIMALS; ARTERIES; ATHEROSCLEROSIS; DENDRITIC CELLS; HUMANS; INFLAMMATION; LIPID METABOLISM; PHENOTYPE; VACCINATION;

EID: 80155214112     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-05-0296     Document Type: Article

References (84)

1. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-126.
2. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
3. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
4. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008; 8: 802-815.
5. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011; 145: 341-355.
6. Lahoute C, Herbin O, Mallat Z, et al. Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol 2011; 8: 348-358.
7. Perrins CJ, Bobryshev YV. Current advances in understanding of immunopathology of atherosclerosis. Virchows Arch 2011; 458: 117-123.
8. Bobryshev YV. Dendritic cells and their role in atherogenesis. Lab Invest 2010; 90: 970-984.
9. Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 2007; 7: 19-30.
10. Naik SH. Demystifying the development of dendritic cell subtypes, a little. Immunol Cell Biol 2008; 86: 439-452.
11. Ju X, Clark G, Hart DN. Review of human DC subtypes. Methods Mol Biol 2010; 595: 3-20.
12. Miloud T, Hammerling GJ, Garbi N. Review of murine dendritic cells: types, location, and development. Methods Mol Biol 2010; 595: 21-42.
13. Geissmann F, Manz MG, Jung S, et al. Development of monocytes, macrophages, and dendritic cells. Science 2010; 327: 656-661.
14. Geissmann F, Gordon S, Hume DA, et al. Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol 2010; 10: 453-460.
15. Galkina E, Kadl A, Sanders J, et al. Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J Exp Med 2006; 203: 1273-1282.
16. Weber C, Meiler S, Döring Y, et al. CCL17-expressing dendritic cells drive atherosclerosis by restraining regulatory T-cell homeostasis in mice. J Clin Invest 2011; in press.
17. Liu P, Yu YR, Spencer JA, et al. CX3CR1 deficiency impairs dendritic cell accumulation in arterial intima and reduces atherosclerotic burden. Arterioscler Thromb Vasc Biol 2008; 28: 243-250.
18. Bobryshev YV. Dendritic cells in atherosclerosis: current status of the problem and clinical relevance. Eur Heart J 2005; 26: 1700-1704.
19. Yilmaz A, Lochno M, Traeg F, et al. Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis 2004; 176: 101-110.
20. Erbel C, Sato K, Meyer FB, et al. Functional profile of activated dendritic cells in unstable atherosclerotic plaque. Basic Res Cardiol 2007; 102: 123-132.
21. Yilmaz A, Weber J, Cicha I, et al. Decrease in circulating myeloid dendritic cell precursors in coronary artery disease. J Am Coll Cardiol 2006; 48: 70-80.
22. Van Vre EA, Hoymans VY, Bult H, et al. Decreased number of circulating plasmacytoid dendritic cells in patients with atherosclerotic coronary artery disease. Coron Artery Dis 2006; 17: 243-248.
23. Van Vre EA, Van Brussel I, de Beeck KO, et al. Changes in blood dendritic cell counts in relation to type of coronary artery disease and brachial endothelial cell function. Coron Art Dis 2010; 21: 87-96.
24. Millonig G, Niederegger H, Rabl W, et al. Network of vascular-associated dendritic cells in intima of healthy young individuals. Arterioscler Thromb Vasc Biol 2001; 21: 503-508.
25. Jongstra-Bilen J, Haidari M, Zhu SN, et al. Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis. J Exp Med 2006; 203: 2073-2083.
26. Choi JH, Do Y, Cheong C, et al. Identification of antigen-presenting dendritic cells in mouse aorta and cardiac valves. J Exp Med 2009; 206: 497-505.
27. Cybulsky MI, Jongstra-Bilen J. Resident intimal dendritic cells and the initiation of atherosclerosis. Curr Opin Lipidol 2010; 21: 397-403.
28. Tacke F, Alvarez D, Kaplan TJ, et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 2007; 117: 185-194.
29. Auffray C, Fogg D, Garfa M, et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 2007; 317: 666-670.
30. Landsman L, Bar-On L, Zernecke A, et al. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 2009; 113: 963-972.
31. Wu H, Gower RM, Wang H, et al. Functional role of CD11c+ monocytes in atherogenesis associated with hypercholesterolemia. Circulation 2009; 119: 2708-2717.
32. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003; 19: 71-82.
33. Swirski FK, Libby P, Aikawa E, et al. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007; 117: 195-205.
34. Zhu SN, Chen M, Jongstra-Bilen J, et al. GM-CSF regulates intimal cell proliferation in nascent atherosclerotic lesions. The Journal of experimental medicine 2009; 206: 2141-2149.
35. Shaposhnik Z, Wang X, Weinstein M, et al. Granulocyte macrophage colonystimulating factor regulates dendritic cell content of atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2007; 27: 621-627.
36. Ditiatkovski M, Toh BH, Bobik A. GM-CSF deficiency reduces macrophage PPAR-gamma expression and aggravates atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2006; 26: 2337-2344.
37. Randolph GJ, Potteaux S. Vascular dendritic cells as gatekeepers of lipid accumulation within nascent atherosclerotic plaques. Circulation Res 2010; 106: 227-229.
38. Paulson KE, Zhu SN, Chen M, et al. Resident Intimal Dendritic Cells Accumulate Lipid and Contribute to the Initiation of Atherosclerosis. Circ Res 2009; 106: 383-390.
39. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nature immunology 2011; 12: 204-212.
40. Alderman CJ, Bunyard PR, Chain BM, et al. Effects of oxidised low density lipoprotein on dendritic cells: a possible immunoregulatory component of the atherogenic micro-environment? Cardiovasc Res 2002; 55: 806-819.
41. Zaguri R, Verbovetski I, Atallah M, et al. 'Danger' effect of low-density lipoprotein (LDL) and oxidized LDL on human immature dendritic cells. Clin Exp Immunol 2007; 149: 543-552.
42. Nickel T, Schmauss D, Hanssen H, et al. oxLDL uptake by dendritic cells induces upregulation of scavenger-receptors, maturation and differentiation. Atherosclerosis 2009; 205: 442-450.
43. Cho HJ, Shashkin P, Gleissner CA, et al. Induction of dendritic cell-like phenotype in macrophages during foam cell formation. Physiol Genomics 2007; 29: 149-160.
44. Angeli V, Llodra J, Rong JX, et al. Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 2004; 21: 561-574.
45. Gautier EL, Huby T, Saint-Charles F, et al. Conventional dendritic cells at the crossroads between immunity and cholesterol homeostasis in atherosclerosis. Circulation 2009; 119: 2367-2375.
46. Gautier EL, Huby T, Witztum JL, et al. Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage. Circulation 2009; 119: 1795-1804.
47. Han JW, Shimada K, Ma-Krupa W, et al. Vessel wall-embedded dendritic cells induce T-cell autoreactivity and initiate vascular inflammation. Circ Res 2008; 102: 546-553.
48. Hermansson A, Ketelhuth DF, Strodthoff D, et al. Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis. J Exp Med 2010; 207: 1081-1093.
49. Paulsson G, Zhou X, Tornquist E, et al. Oligoclonal T cell expansions in atherosclerotic lesions of apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2000; 20: 10-17.
50. Sun J, Hartvigsen K, Chou MY, et al. Deficiency of antigen-presenting cell invariant chain reduces atherosclerosis in mice. Circulation 2010; 122: 808-820.
51. Packard RR, Maganto-Garcia E, Gotsman I, et al. CD11c(+) dendritic cells maintain antigen processing, presentation capabilities, and CD4(+) T-cell priming efficacy under hypercholesterolemic conditions associated with atherosclerosis. Circ Res 2008; 103: 965-973.
52. Shamshiev AT, Ampenberger F, Ernst B, et al. Dyslipidemia inhibits Toll-like receptor-induced activation of CD8alpha-negative dendritic cells and protective Th1 type immunity. J Exp Med 2007; 204: 441-452.
53. Zhou X, Paulsson G, Stemme S, et al. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest 1998; 101: 1717-1725.
54. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008; 79: 360-376.
55. Binder CJ, Hartvigsen K, Chang MK, et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 2004; 114: 427-437.
56. Mallat Z, Besnard S, Duriez M, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85: e17-24.
57. Ait-Oufella H, Salomon BL, Potteaux S, et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006; 12: 178-180.
58. Taleb S, Romain M, Ramkhelawon B, et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 2009; 206: 2067-2077.
59. van Es T, van Puijvelde GH, Ramos OH, et al. Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem Biophys Res Commun 2009; 388: 261-265.
60. Braunersreuther V, Zernecke A, Arnaud C, et al. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2007; 27: 373-379.
61. Gotsman I, Grabie N, Gupta R, et al. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 2006; 114: 2047-2055.
62. Grabner R, Lotzer K, Dopping S, et al. Lymphotoxin beta receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE-/- mice. J Exp Med 2009; 206: 233-248.
63. Randolph GJ. Emigration of monocyte-derived cells to lymph nodes during resolution of inflammation and its failure in atherosclerosis. Curr Opin Lipidol 2008; 19: 462-468.
64. Trogan E, Feig JE, Dogan S, et al. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci USA 2006; 103: 3781-3786.
65. Potteaux S, Gautier EL, Hutchison SB, et al. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression. J Clin Invest 2011; 121: 2025-2036.
66. Luchtefeld M, Grothusen C, Gagalick A, et al. Chemokine receptor 7 knockout attenuates atherosclerotic plaque development. Circulation 2010; 122: 1621-1628.
67. Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol 2008; 28: 1897-1908.
68. Bernhagen J, Krohn R, Lue H, et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007; 13: 587-596.
69. Tacken PJ, de Vries IJ, Torensma R, et al. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007; 7: 790-802.
70. Palucka K, Ueno H, Banchereau J. Recent developments in cancer vaccines. J Immunol 2011; 186: 1325-1331.
71. Hansson GK, Nilsson J. Vaccination against atherosclerosis? Induction of atheroprotective immunity. Semin Immunopathol 2009; 31: 95-101.
72. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006; 6: 508-519.
73. Ludewig B, Freigang S, Jaggi M, et al. Linking immune-mediated arterial inflammation and cholesterol-induced atherosclerosis in a transgenic mouse model. Proc Natl Acad Sci USA 2000; 97: 12752-12757.
74. Habets KL, van Puijvelde GH, van Duivenvoorde LM, et al. Vaccination using oxLDL-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice. Cardiovasc Res 2009; 85: 622-630.
75. Hjerpe C, Johansson D, Hermansson A, et al. Dendritic cells pulsed with malondialdehyde modified low density lipoprotein aggravate atherosclerosis in Apoe(-/-) mice. Atherosclerosis 2010; 209: 436-441.
76. Hermansson A, Johansson DK, Ketelhuth DF, et al. Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice. Circulation 2011; 123: 1083-1091.
77. Colonna M, Trinchieri G, Liu YJ. Plasmacytoid dendritic cells in immunity. Nat Immunol 2004; 5: 1219-1226.
78. Niessner A, Shin MS, Pryshchep O, et al. Synergistic proinflammatory effects of the antiviral cytokine interferon-alpha and Toll-like receptor 4 ligands in the atherosclerotic plaque. Circulation 2007; 116: 2043-2052.
79. Niessner A, Weyand CM. Dendritic cells in atherosclerotic disease. Clin Immunol 2010; 134: 25-32.
80. Sorrentino R, Morello S, Pinto A. Plasmacytoid dendritic cells: from heart to vessels. Int J Vasc Med 2010; 2010: 430318.
81. Niessner A, Sato K, Chaikof EL, et al. Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon- alpha. Circulation 2006; 114: 2482-2489.
82. Marshak-Rothstein A, Busconi L, Rifkin IR, et al. The stimulation of Toll-like receptors by nuclear antigens: a link between apoptosis and autoimmunity. Rheum Dis Clin North Am 2004; 30: 559-574, ix.
83. Ochando JC, Homma C, Yang Y, et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol 2006; 7: 652-662.
84. Nilsson J, Hansson GK, Shah PK. Immunomodulation of atherosclerosis: implications for vaccine development. Arterioscler Thromb Vasc Biol 2005; 25: 18-28.